Metoprolol may increase the hypotensive activities of Enalaprilat. The serum concentration of Metoprolol can be increased when it is combined with Etoricoxib. Barbital may increase the hypotensive activities of Metoprolol. The risk or severity of adverse effects can be increased when Tretinoin is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Temsirolimus. The risk or severity of adverse effects can be increased when Bepridil is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Niacin. Metoprolol may increase the hypotensive activities of Unoprostone. Metoprolol may decrease the bronchodilatory activities of Arbutamine. The serum concentration of Metoprolol can be decreased when it is combined with Lumacaftor. Tiaprofenic acid may decrease the antihypertensive activities of Metoprolol. Metoprolol may increase the bradycardic activities of Lucinactant. The metabolism of Nateglinide can be decreased when combined with Metoprolol. The serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Ritonavir. The serum concentration of Bupivacaine can be increased when it is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Alaproclate. Pargyline may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Vinorelbine. Anisodamine may decrease the antihypertensive activities of Metoprolol. Toloxatone may increase the hypotensive activities of Metoprolol. The metabolism of Zalcitabine can be decreased when combined with Metoprolol. Metoprolol may increase the hypotensive activities of Ticrynafen. The serum concentration of Metoprolol can be increased when it is combined with Simvastatin. Metoprolol may increase the bradycardic activities of Ivabradine. Evening primrose oil may decrease the antihypertensive activities of Metoprolol. The metabolism of Dihydrocodeine can be decreased when combined with Metoprolol. Donepezil may increase the bradycardic activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Diltiazem. The serum concentration of Metoprolol can be increased when it is combined with Zimelidine. The serum concentration of Metoprolol can be increased when it is combined with Ketoconazole. Levonordefrin may increase the atrioventricular blocking (AV block) activities of Metoprolol. Pyridostigmine may increase the bradycardic activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Dexmedetomidine. The serum concentration of Topotecan can be increased when it is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Labetalol. Pirfenidone may decrease the antihypertensive activities of Metoprolol. Reserpine may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Betaxolol. Bromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol. Metoprolol may increase the hypotensive activities of Cryptenamine. The risk or severity of adverse effects can be increased when Metoprolol is combined with Hydralazine. Nitroaspirin may decrease the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Desipramine. The serum concentration of Metoprolol can be increased when it is combined with Metoclopramide. 1,10-Phenanthroline may increase the bradycardic activities of Metoprolol. Metoprolol may increase the hypoglycemic activities of Acetohexamide. Nicorandil may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine. Metoprolol may increase the bradycardic activities of Oleandrin. The serum concentration of Metoprolol can be increased when it is combined with Abiraterone. Tenoxicam may decrease the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Proguanil. The metabolism of Alogliptin can be decreased when combined with Metoprolol. Metoprolol may increase the hypotensive activities of Amifostine. The serum concentration of Metoprolol can be increased when it is combined with Deramciclane. The serum concentration of Metoprolol can be increased when it is combined with Ondansetron. Metoprolol may increase the vasoconstricting activities of Cabergoline. The metabolism of Zolpidem can be decreased when combined with Metoprolol. The metabolism of Metoprolol can be increased when combined with Phenytoin. The risk or severity of adverse effects can be increased when Metoprolol is combined with Riociguat. The risk or severity of adverse effects can be increased when Metoprolol is combined with Captopril. Mebanazine may increase the hypotensive activities of Metoprolol. The metabolism of Enclomiphene can be decreased when combined with Metoprolol. The therapeutic efficacy of Metoprolol can be decreased when used in combination with Acemetacin. The serum concentration of Metoprolol can be increased when it is combined with Celecoxib. The serum concentration of Metoprolol can be increased when it is combined with Perphenazine. The serum concentration of Metoprolol can be increased when it is combined with Cyproterone acetate. The metabolism of Dasabuvir can be decreased when combined with Metoprolol. Piroxicam may decrease the antihypertensive activities of Metoprolol. The risk or severity of adverse effects can be increased when Arotinolol is combined with Metoprolol. The metabolism of Ethylmorphine can be decreased when combined with Metoprolol. Guanabenz may increase the atrioventricular blocking (AV block) activities of Metoprolol. Gallamine Triethiodide may increase the bradycardic activities of Metoprolol. Azapropazone may decrease the antihypertensive activities of Metoprolol. Rilmenidine may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Bupropion. Metoprolol may increase the hypotensive activities of Latanoprost. Metoprolol may increase the hypotensive activities of Theodrenaline. Disopyramide may increase the bradycardic activities of Metoprolol. Lercanidipine may increase the hypotensive activities of Metoprolol. Benmoxin may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Chloroquine. The serum concentration of Metoprolol can be increased when it is combined with Irbesartan. Demecarium may increase the bradycardic activities of Metoprolol. The risk or severity of adverse effects can be increased when Metoprolol is combined with Amiloride. Metoprolol may increase the hypotensive activities of Trichlormethiazide. Xylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol. Propericiazine may increase the hypotensive activities of Metoprolol. Metoprolol may increase the hypoglycemic activities of Insulin Pork. Furazolidone may increase the hypotensive activities of Metoprolol. Isoxicam may decrease the antihypertensive activities of Metoprolol. Ginkgo biloba may increase the bradycardic activities of Metoprolol. Fenoprofen may decrease the antihypertensive activities of Metoprolol. Metoprolol may increase the bradycardic activities of Ceritinib. Droxicam may decrease the antihypertensive activities of Metoprolol. Tolmetin may decrease the antihypertensive activities of Metoprolol. Thiethylperazine may increase the hypotensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Atomoxetine. Minaprine may increase the bradycardic activities of Metoprolol. Metoprolol may decrease the bronchodilatory activities of Pirbuterol. The serum concentration of Metoprolol can be increased when it is combined with Tipranavir. The serum concentration of Metoprolol can be increased when it is combined with Midostaurin. Tranilast may decrease the antihypertensive activities of Metoprolol. The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metoprolol. The risk or severity of adverse effects can be increased when Imidapril is combined with Metoprolol. The metabolism of Ixazomib can be decreased when combined with Metoprolol. Alfentanil may increase the bradycardic activities of Metoprolol. Masoprocol may decrease the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Hydroxychloroquine. The metabolism of Benzyl alcohol can be decreased when combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Miconazole. Parthenolide may decrease the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Pimozide. The serum concentration of Metoprolol can be increased when it is combined with Glycerol Phenylbutyrate. Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Metoprolol. The serum concentration of Edoxaban can be increased when it is combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Phentermine. Salicylamide may decrease the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Nortriptyline. Avanafil may increase the antihypertensive activities of Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Fexofenadine. The metabolism of Almotriptan can be decreased when combined with Metoprolol. The metabolism of Pethidine can be decreased when combined with Metoprolol. The serum concentration of Metoprolol can be increased when it is combined with Mepyramine. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol. Resveratrol may decrease the antihypertensive activities of Metoprolol. The metabolism of Dopamine can be decreased when combined with Metoprolol. Molsidomine may increase the hypotensive activities of Metoprolol. Metoprolol may increase the orthostatic hypotensive activities of Doxazosin.